U.S. markets closed

La Jolla Pharmaceutical Company (LJPC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.24-0.62 (-10.58%)
At close: 4:00PM EST
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Breakdown
ttm
12/31/2019
12/31/2018
12/31/2017
Total Revenue
23,054
23,054
10,056
0
Cost of Revenue
4,800
2,392
1,643
-
Gross Profit
20,662
20,662
8,413
-
Operating Expense
130,463
130,463
202,464
115,427
Operating Income
-109,801
-109,801
-194,051
-115,427
Net Non Operating Interest Income Expense
-9,234
-8,646
-5,418
-
Other Income Expense
1,939
1,939
-
624
Pretax Income
-116,508
-116,508
-199,469
-114,803
Net Income Common Stockholders
-116,508
-116,508
-199,469
-114,803
Diluted NI Available to Com Stockholders
-116,508
-116,508
-199,469
-114,803
Basic EPS
-
-0.0043
-0.0079
-0.0054
Diluted EPS
-
-0.0043
-0.0079
-0.0054
Basic Average Shares
-
27,112
25,422
21,215
Diluted Average Shares
-
27,112
25,422
21,215
Total Operating Income as Reported
-57,554
-109,801
-194,051
-115,427
Total Expenses
132,855
132,855
204,107
115,427
Net Income from Continuing & Discontinued Operation
-116,508
-116,508
-199,469
-114,803
Normalized Income
-116,508
-116,508
-199,469
-114,803
Interest Income
2,128
2,128
1,885
-
Interest Expense
9,778
10,774
7,303
-
Net Interest Income
-8,646
-8,646
-5,418
-
EBIT
-105,734
-105,734
-192,166
-115,427
EBITDA
-101,182
-
-
-
Reconciled Cost of Revenue
2,392
2,392
1,643
-
Reconciled Depreciation
4,552
4,552
4,405
1,268
Net Income from Continuing Operation Net Minority Interest
-116,508
-116,508
-199,469
-114,803
Normalized EBITDA
-101,182
-101,182
-187,761
-114,159
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0